Amgen (AMGN): SVP & CCO sold ~$484K

~$484K

Approx. value · 1,589 sh @ $304.47

7,210

Holds after · shares reported

Traded

Feb 5, 2025

Filed

Feb 7, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 6, 2024CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
2. Dec 26, 2024FDAFDA drug approval: Wezlana
3. Jan 6, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
4. Jan 16, 2025FDAFDA drug approval: Lumakras
5. Jan 16, 2025FDAFDA drug approval: Vectibix
6. Feb 5, 2025 · this disclosureInsiderOfficer sold ~$484K of AMGN shares in the open market

What came next

1. Feb 7, 2025InsiderOfficer sold ~$7.34M of AMGN shares in the open market
2. Feb 11, 2025InsiderOfficer sold ~$2.59M of AMGN shares in the open market
3. Feb 18, 2025InsiderOfficer sold ~$146K of AMGN shares in the open market
4. Feb 19, 2025Insider · 3 peopleInsiders: 3 sales (~$5.6M)
5. Feb 21, 2025InsiderOfficer sold ~$7.68M of AMGN shares in the open market
6. Feb 24, 2025CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
7. Feb 27, 2025FDARecall: Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative…
8. Feb 27, 2025FDARecall: Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL single Dose Vial, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solutio…
9. Apr 7, 2025FDAFDA drug approval: Amjevita
10. Apr 8, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
11. Apr 11, 2025CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
12. Apr 15, 2025CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
13. Apr 16, 2025Congress · 1 personMembers of Congress: 2 purchases
14. May 2, 2025InsiderOfficer sold ~$280K of AMGN shares in the open market
15. May 5, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
16. May 14, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
17. May 20, 2025FDAFDA drug approval: Amjevita
18. May 22, 2025FDAFDA drug approval: Prolia

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Amgen

For Amgen, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

Other recent filings by Nancy A. Grygiel, SVP & CCO

• SEC Form 4 at Amgen (AMGN)Aug 7, 2026
• SEC Form 4 at Amgen (AMGN)Aug 7, 2026
• SEC Form 4 at Amgen (AMGN)May 6, 2026
• SEC Form 4 at Amgen (AMGN)Nov 22, 2025
• SEC Form 4 at Amgen (AMGN)Nov 22, 2025

The full history of Nancy A. Grygiel, SVP & CCO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Amgen

• House Clerk periodic transaction reportOct 1, 2026
• House Clerk periodic transaction reportSep 5, 2026
• House Clerk periodic transaction reportSep 5, 2026
• Senate eFD periodic transaction reportSep 2, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its AMGN page.